Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...
Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results